title: [A case of ascending colon cancer with local recurrence responding completely to alternating modified-FOLFOX6 and FOLFIRI regimens(modified-FIREFOX regimen)].
abstract: A 58-year-old woman underwent right hemicolectomy with lymph node dissection(D2)for advanced ascending colon cancer which pathological examinations revealed to be moderately-differentiated adenocarcinoma. CEA and CA19-9 levels increased 6 months after the operation. She started adjuvant chemotherapy with oral administration of UFT-E(400 mg/day), but CEA and CA19-9 levels continued to elevate. However, a recurrent tumor was not detected by computed tomography(CT)and endoscopic examinations. A local recurrence in the right lateral abdominal wall was confirmed by PET-CT examination. We then conducted modified-FOLFOX6/FOLFIRI alternating regimen(modified- FIREFOX regimen). After this therapy, repeated PET-CT showed that the abnormal FDG-uptake concentration had disappeared, leading to a complete response(CR). The adverse event was grade 3 in leucopenia and grade 2 in gastrointestinal toxicity. She had maintained CR for the 12 months since undergoing chemotherapy. CEA and CA19-9 levels reduced to the normal range. We report this case with some review of the literature.
authors.affiliation: Dept. of Surgery, Nippon Medical School Tama-Nagayama Hospital.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Matsutani
authors.forename: Koji
authors.initials: K
authors.lastname: Sasajima
authors.forename: Seiji
authors.initials: S
authors.lastname: Suzuki
authors.forename: Akira
authors.initials: A
authors.lastname: Matsushita
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Maruyama
authors.forename: Akihisa
authors.initials: A
authors.lastname: Matsuda
authors.forename: Masayuki
authors.initials: M
authors.lastname: Miyamoto
authors.forename: Tadashi
authors.initials: T
authors.lastname: Yokoyama
authors.forename: Atsushi
authors.initials: A
authors.lastname: Sugiura
authors.forename: Ken
authors.initials: K
authors.lastname: Yanagi
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Nishi
authors.forename: Hiroki
authors.initials: H
authors.lastname: Arai
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Wakabayashi
authors.forename: Takashi
authors.initials: T
authors.lastname: Tajiri
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000097:blood; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D049268:Positron-Emission Tomography; D012008:Recurrence; D012074:Remission Induction; D014057:Tomography, X-Ray Computed
chemical_list: D014408:Biomarkers, Tumor; D009944:Organoplatinum Compounds; D002955:Leucovorin; D005472:Fluorouracil; D002166:Camptothecin